North American Protein Degradation Conference
Plus Pre-conference deep dive into ‘Drugging the Proteasome’
February 4-6, 2020
San Diego, USA
“The entire bandwidth of the protein degradation field was covered with excellent, carefully prepared presentations” - Peter von Matt, Novartis
With Arvinas’ PROTAC therapy entering phase 1 clinical trials, Kymeras’ IRAK4 degrader racing through pre-clinical, and Bristol-Myers Squibb approaching complete acquisition of Celgene, it has never been a more exciting time to be working in the field of targeted protein degradation.
Following the global response to the inaugural European Congress earlier this year, the North American Protein Degradation Congress will bring together pharma, biotech, and academic researchers to expand upon one of the hottest drug discovery platforms within the pharmaceutical industry. Delegates will have the opportunity to learn from experts and key thought leaders within the protein degradation space, allowing ideas to be exchanged, partnerships to be built, and difficulties to be addressed in expanding the space of protein degraders beyond our current knowledge.
At the congress, you can expect to hear the following:
- The latest pre-clinical and clinical data in PROTAC therapy and molecular glues
- Emerging strategies outside of PROTACs and molecular glues to induce TPD
- Assessing rates of protein synthesis, degradation, and quantifying protein homeostatic in vivo
- Insights into protein degrader PK/PD from mechanistic modelling